NanoBio Corp. is expected to look for a major pharmaceutical partner after securing about $11 million in funding from investors, including Perseus LLC. The company hopes to begin late-stage trials of its anti-fungal and cold-sore drugs next year, said James Baker, NanoBio's executive chairman and chief science officer.

Related Summaries